Article
The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma.
Journal of gastroenterology - 1 Feb 2011
Hagiwara Satoru, Kudo Masatoshi, Ueshima Kazuomi, Chung Hobyung, Yamaguchi Mami, Takita Masahiro, Haji Seiji, Kimura Masatomo, Arao Tokuzo, Nishio Kazuto, Park Ah-Mee, Munakata Hiroshi
Abstract excerpt
BACKGROUND: Combination therapy with the oral fluoropyrimidine anticancer drug S1 and interferon is reportedly effective for the treatment of advanced hepatocellular carcinoma (HCC), but selection criteria for this therapy have not been clarified. In this study, we attempted to identify factors predicting the effectiveness of this combination therapy. METHODS: Pathological specimens of HCC were collected before...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.